Table 5 Pairwise meta-analyses for non-hematological toxicities of different CCRT regimens in the treatment of LA-NSCLC
Included studies | Comparisons | Toxicity events | Pairwise meta-analysis | |||
|---|---|---|---|---|---|---|
Treatment 1 | Treatment 2 | OR (95% CI) | I2 | P | ||
Nausea/vomiting | ||||||
 2 studies | E VS. I | 6/56 | 5/56 | 1.22 (0.35–4.27) | 0.0% | 0.810 |
 2 studies | I VS. K | 26/173 | 21/176 | 1.32 (0.70–2.47) | 0.0% | 0.887 |
 2 studies | J VS. R | 1/121 | 1/122 | 1.01 (0.06–16.31) | 0.0% | 0.996 |
 1 study | A VS. B | 2/31 | 1/44 | 2.97 (0.26–34.24) | NA | NA |
 1 study | A VS. D | 24/272 | 20/283 | 1.27 (0.69–2.36) | NA | NA |
 1 study | A VS. E | 1/50 | 2/55 | 0.54 (0.05–6.15) | NA | NA |
 1 study | A VS. M | 11/95 | 19/96 | 0.53 (0.24–1.19) | NA | NA |
 1 study | B VS. G | 5/151 | 43/153 | 0.09 (0.03–0.23) | NA | NA |
 1 study | B VS. N | 5/151 | 7/152 | 0.71 (0.22–2.29) | NA | NA |
 1 study | D VS. H | 3/52 | 1/48 | 2.88 (0.29–28.65) | NA | NA |
 1 study | E VS. G | 8/99 | 5/101 | 1.69 (0.53–5.35) | NA | NA |
 1 study | G VS. N | 43/153 | 7/152 | 8.10 (3.51–18.69) | NA | NA |
 1 study | F VS. H | 4/35 | 2/31 | 1.87 (0.32–11.00) | NA | NA |
 1 study | K VS. L | 3/101 | 7/99 | 0.40 (0.10–1.60) | NA | NA |
 1 study | K VS. O | 2/47 | 19/60 | 0.22 (0.02–2.03) | NA | NA |
Esophagitis | ||||||
 2 studies | A VS. B | 23/64 | 28/76 | 0.96 (0.48–1.92) | 0.0% | 0.733 |
 3 studies | K VS. R | 8/174 | 14/176 | 0.56 (0.23–1.37) | 0.0% | 0.902 |
 2 studies | F VS. I | 4/56 | 2/56 | 2.08 (0.36–11.83) | 0.0% | 0.989 |
 2 studies | I VS. K | 22/173 | 14/176 | 1.69 (0.83–3.41) | 0.0% | 0.439 |
 1 study | A VS. D | 21/272 | 22/283 | 0.99 (0.53–1.85) | NA | NA |
 1 study | A VS. E | 3/50 | 3/55 | 1.11 (0.21–5.75) | NA | NA |
 1 study | A VS. M | 19/95 | 6/96 | 3.75 (1.43–9.87) | NA | NA |
 1 study | B VS. G | 11/151 | 6/153 | 1.92 (0.69–5.35) | NA | NA |
 1 study | B VS. N | 11/151 | 3/152 | 3.90 (1.07–14.28) | NA | NA |
 1 study | C VS. D | 1/9 | 1/13 | 1.50 (0.08–27.61) | NA | NA |
 1 study | D VS. H | 1/52 | 3/48 | 0.29 (0.03–2.93) | NA | NA |
 1 study | E VS. G | 14/99 | 6/101 | 2.61 (0.96–7.09) | NA | NA |
 1 study | F VS. H | 1/35 | 1/31 | 0.88 (0.05–14.73) | NA | NA |
 1 study | G VS. N | 6/153 | 3/152 | 2.03 (0.50–8.26) | NA | NA |
 1 study | K VS. L | 3/101 | 11/99 | 0.24 (0.07–0.91) | NA | NA |
 1 study | K VS. O | 2/47 | 5/60 | 0.49 (0.09–2.64) | NA | NA |
 1 study | K VS. P | 7/66 | 8/65 | 0.85 (029–2.48) | NA | NA |
 1 study | K VS. Q | 1/20 | 1/21 | 1.05 (0.06–18.05) | NA | NA |
Pneumonitis | ||||||
 2 studies | A VS. B | 10/64 | 18/76 | 0.60 (0.25–1.40) | 40.9% | 0.193 |
 2 studies | F VS. I | 3/56 | 2/56 | 1.53 (0.25–9.52) | 0.0% | 0.706 |
 2 studies | K VS. R | 8/121 | 14/122 | 0.55 (0.22–1.35) | 0.0% | 0.648 |
 1 study | A VS. D | 7/272 | 6/283 | 1.22 (0.40–3.68) | NA | NA |
 1 study | A VS. E | 1/50 | 6/55 | 0.17 (0.02–1.35) | NA | NA |
 1 study | A VS. J | 6/26 | 1/27 | 7.80 (0.87–70.10) | NA | NA |
 1 study | A VS. M | 18/95 | 32/96 | 0.47 (0.24–0.91) | NA | NA |
 1 study | B VS. G | 16/151 | 35/153 | 0.40 (0.21–0.76) | NA | NA |
 1 study | B VS. N | 16/151 | 19/152 | 0.83 (0.41–1.68) | NA | NA |
 1 study | C VS. D | 1/9 | 1/13 | 1.50 (0.08–27.61) | NA | NA |
 1 study | D VS. H | 1/52 | 1/48 | 0.92 (0.06–15.15) | NA | NA |
 1 study | E VS. G | 10/99 | 7/101 | 1.51 (0.55–4.14) | NA | NA |
 1 study | F VS. H | 2/35 | 4/31 | 0.41 (0.07–2.41) | NA | NA |
 1 study | G VS. N | 35/153 | 19/152 | 2.08 (1.13–3.83) | NA | NA |
 1 study | I VS. K | 24/88 | 22/88 | 1.13 (0.57–2.21) | NA | NA |
 1 study | K VS. O | 1/47 | 3/60 | 0.41 (0.04–4.10) | NA | NA |
 1 study | K VS. P | 5/66 | 7/65 | 0.68 (0.19–5.99) | NA | NA |
 1 study | K VS. Q | 3/20 | 3/21 | 1.39 (0.62–3.11) | NA | NA |